{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:55:54Z","timestamp":1771300554803,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":364,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2018]]},"DOI":"10.6061\/clinics\/2018\/e813s","type":"journal-article","created":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T06:37:12Z","timestamp":1543732632000},"page":"e813s","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"S1","title":["Natural products as new antimitotic compounds for anticancer drug development"],"prefix":"10.1016","volume":"73","author":[{"given":"Carlos Roberto Koscky","family":"Paier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Sant'Anna","family":"Maranh\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiliane Rodrigues","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00eddia Moreira","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo Damasceno","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renan","family":"da Silva Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaio Moraes","family":"de Farias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoel Odorico","family":"de Moraes-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.6061\/clinics\/2018\/e813s_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bcp.2013.07.010","article-title":"Antimitotic drugs in cancer chemotherapy: promises and pitfalls","volume":"86","author":"Marzo","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00063030-200721040-00003","article-title":"Targeting mitosis for anti-cancer therapy","volume":"21","author":"Sudakin","year":"2007","journal-title":"BioDrugs"},{"key":"10.6061\/clinics\/2018\/e813s_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pharmthera.2017.02.007","article-title":"Anti-mitotic agents: are they emerging molecules for cancer treatment?","volume":"173","author":"Penna","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"17","key":"10.6061\/clinics\/2018\/e813s_bib6","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1242\/dev.153171","article-title":"Microtubule organization, dynamics and functions in differentiated cells","volume":"144","author":"Muroyama","year":"2017","journal-title":"Development"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib7","first-page":"54","article-title":"Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins","volume":"7","author":"Harrison","year":"2009","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.hoc.2012.01.007","article-title":"Antimitotic inhibitors","volume":"26","author":"Campos","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Pt 15","key":"10.6061\/clinics\/2018\/e813s_bib9","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1242\/jcs.039719","article-title":"How do anti-mitotic drugs kill cancer cells?","volume":"122","author":"Gascoigne","year":"2009","journal-title":"J Cell Sci"},{"issue":"5441","key":"10.6061\/clinics\/2018\/e813s_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.286.5441.971","article-title":"Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen","volume":"286","author":"Mayer","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrc2049","article-title":"Targeted anti-mitotic therapies: can we improve on tubulin agents?","volume":"7","author":"Jackson","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4155\/fmc.16.5","article-title":"Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy","volume":"8","author":"Myers","year":"2016","journal-title":"Future Med Chem"},{"issue":"8","key":"10.6061\/clinics\/2018\/e813s_bib13","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1158\/1535-7163.MCT-14-0083-T","article-title":"Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer","volume":"13","author":"Kung","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1535-7163.MCT-08-0789","article-title":"UA62784, a novel inhibitor of centromere protein E kinesin-like protein","volume":"8","author":"Henderson","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.6061\/clinics\/2018\/e813s_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144675","article-title":"A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity","volume":"10","author":"Ohashi","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00280-011-1756-z","article-title":"First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer","volume":"69","author":"Chung","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.6061\/clinics\/2018\/e813s_bib17","first-page":"535","article-title":"Differential gene expression analysis of kinesin spindle protein in human solid tumors","volume":"22","author":"Hegde","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ncb2689","article-title":"A genomic toolkit to investigate kinesin and myosin motor function in cells","volume":"15","author":"Maliga","year":"2013","journal-title":"Nat Cell Biol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pharmthera.2013.12.010","article-title":"Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors","volume":"142","author":"Pitts","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.6061\/clinics\/2018\/e813s_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib21","first-page":"73","article-title":"Cyclin D-dependent kinases, INK4 inhibitors and cancer","volume":"1602","author":"Ortega","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"19","key":"10.6061\/clinics\/2018\/e813s_bib22","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.2174\/092986711796150496","article-title":"Peptides or small molecules? Different approaches to develop more effective CDK inhibitors","volume":"18","author":"Cirillo","year":"2011","journal-title":"Curr Med Chem"},{"issue":"7","key":"10.6061\/clinics\/2018\/e813s_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/cbt.19589","article-title":"Cyclin dependent kinases in cancer: potential for therapeutic intervention","volume":"13","author":"Canavese","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0898-6568(00)00080-2","article-title":"The human polo-like kinase, PLK, regulates cdc2\/cyclin B through phosphorylation and activation of the cdc25C phosphatase","volume":"12","author":"Roshak","year":"2000","journal-title":"Cell Signal"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129313","article-title":"Upregulated Polo-like Kinase 1 expression correlates with inferior survival outcomes in rectal cancer","volume":"10","author":"Tut","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000093003","article-title":"Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma","volume":"70","author":"Kanaji","year":"2006","journal-title":"Oncology"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ccr.2005.02.009","article-title":"ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent","volume":"7","author":"Gumireddy","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.6061\/clinics\/2018\/e813s_bib28","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Rudolph","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.6061\/clinics\/2018\/e813s_bib29","doi-asserted-by":"crossref","first-page":"23937","DOI":"10.18632\/oncotarget.14893","article-title":"Aurora kinases: novel therapy targets in cancers","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib30","first-page":"1414","article-title":"Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis","volume":"20","author":"Cirak","year":"2015","journal-title":"J BUON"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00428-014-1577-7","article-title":"BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma","volume":"464","author":"Davidson","year":"2014","journal-title":"Virchows Arch"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-1057-03","article-title":"Overexpression and amplification of Aurora-A in hepatocellular carcinoma","volume":"10","author":"Jeng","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.leukres.2013.11.003","article-title":"Proteins related to the spindle and checkpoint mitotic emphasize the different pathogenesis of hypoplastic MDS","volume":"38","author":"Heredia","year":"2014","journal-title":"Leuk Res"},{"issue":"7","key":"10.6061\/clinics\/2018\/e813s_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2012.06.040","article-title":"Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"127","author":"Matulonis","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib36","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2007-02-073700","article-title":"AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib37","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib38","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/1087057113520325","article-title":"Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors","volume":"19","author":"Guo","year":"2014","journal-title":"J Biomol Screen"},{"issue":"15","key":"10.6061\/clinics\/2018\/e813s_bib39","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-11-2936","article-title":"Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration","volume":"18","author":"Lin","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"Database issue","key":"10.6061\/clinics\/2018\/e813s_bib40","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.6061\/clinics\/2018\/e813s_bib41","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM Mutations in Cancer: therapeutic Implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2407-13-288","article-title":"High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients","volume":"13","author":"Magnussen","year":"2013","journal-title":"BMC Cancer"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib43","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/leu.2011.392","article-title":"Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia","volume":"26","author":"Porter","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2014.07.102","article-title":"Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions","volume":"135","author":"Slipicevic","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"22","key":"10.6061\/clinics\/2018\/e813s_bib45","first-page":"8211","article-title":"Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res"},{"issue":"16","key":"10.6061\/clinics\/2018\/e813s_bib46","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm0512591","article-title":"4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution","volume":"49","author":"Palmer","year":"2006","journal-title":"J Med Chem"},{"issue":"10","key":"10.6061\/clinics\/2018\/e813s_bib47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 Kinase in Cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"28","key":"10.6061\/clinics\/2018\/e813s_bib48","doi-asserted-by":"crossref","first-page":"24733","DOI":"10.18632\/oncotarget.4619","article-title":"The 26S proteasome is a multifaceted target for anti-cancer therapies","volume":"6","author":"Grigoreva","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/17474086.2014.873699","article-title":"The emerging role of carfilzomib combination therapy in the management of multiple myeloma","volume":"7","author":"Moreau","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Proteasome inhibitors","volume":"96","author":"Teicher","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.6061\/clinics\/2018\/e813s_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejmech.2017.01.023","article-title":"Pterocarpan scaffold: A natural lead molecule with diverse pharmacological properties","volume":"128","author":"Selvam","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.6061\/clinics\/2018\/e813s_bib52","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1038\/cddis.2012.148","article-title":"Mitosis-targeted anti-cancer therapies: where they stand","volume":"3","author":"Chan","year":"2012","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1158\/1078-0432.CCR-11-0999","article-title":"Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale","volume":"18","author":"Komlodi-Pasztor","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1091\/mbc.e10-04-0335","article-title":"The proliferation rate paradox in antimitotic chemotherapy","volume":"23","author":"Mitchison","year":"2012","journal-title":"Mol Biol Cell"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2011.197","article-title":"Killing cells by targeting mitosis","volume":"19","author":"Manchado","year":"2012","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib56","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/ci8003336","article-title":"Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity","volume":"49","author":"Freedman","year":"2009","journal-title":"J Chem Inf Model"},{"issue":"9","key":"10.6061\/clinics\/2018\/e813s_bib57","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-05-2715","article-title":"Class III \u03b2-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients","volume":"12","author":"Ferrandina","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.6061\/clinics\/2018\/e813s_bib58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","article-title":"The role of ABC transporters in clinical practice","volume":"8","author":"Leonard","year":"2003","journal-title":"Oncologist"},{"issue":"6 Suppl 7","key":"10.6061\/clinics\/2018\/e813s_bib59","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2005.09.010","article-title":"Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR)","volume":"32","author":"Fojo","year":"2005","journal-title":"Semin Oncol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coph.2013.03.011","article-title":"Mitosis-targeting therapies: a troubleshooting guide","volume":"13","author":"Dom\u00e9nech","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2011.11.001","article-title":"A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours","volume":"48","author":"Sch\u00f6ffski","year":"2012","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.6061\/clinics\/2018\/e813s_bib62","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/annonc\/mdr451","article-title":"A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies","volume":"23","author":"Arkenau","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib63","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10637-013-9926-y","article-title":"Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer","volume":"31","author":"Jones","year":"2013","journal-title":"Invest New Drugs"},{"issue":"24","key":"10.6061\/clinics\/2018\/e813s_bib64","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1016\/j.bmcl.2009.10.064","article-title":"Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs","volume":"19","author":"F\u00fcrst","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2174\/092986711794480221","article-title":"Developments of combretastatin A-4 derivatives as anticancer agents","volume":"18","author":"Shan","year":"2011","journal-title":"Curr Med Chem"},{"issue":"8","key":"10.6061\/clinics\/2018\/e813s_bib66","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1039\/C7MD00227K","article-title":"Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents","volume":"8","author":"Seddigi","year":"2017","journal-title":"MedChemComm"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nano.2011.05.003","article-title":"Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature","volume":"8","author":"Yang","year":"2012","journal-title":"Nanomedicine (Lond)"},{"issue":"9","key":"10.6061\/clinics\/2018\/e813s_bib68","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1021\/jm901826e","article-title":"Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2","volume":"54","author":"Combes","year":"2011","journal-title":"J Med Chem"},{"issue":"11","key":"10.6061\/clinics\/2018\/e813s_bib69","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/138955707782331722","article-title":"Privileged structures: a useful concept for the rational design of new lead drug candidates","volume":"7","author":"Duarte","year":"2007","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085380","article-title":"Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues","volume":"9","author":"do Amaral","year":"2014","journal-title":"PLoS One"},{"issue":"21","key":"10.6061\/clinics\/2018\/e813s_bib71","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1021\/jm060546h","article-title":"Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors","volume":"49","author":"Hu","year":"2006","journal-title":"J Med Chem"},{"issue":"9","key":"10.6061\/clinics\/2018\/e813s_bib72","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1021\/tx200180y","article-title":"Preclinical genotoxicology of nor-\u03b2-lapachone in human cultured lymphocytes and Chinese hamster lung fibroblasts","volume":"24","author":"Cavalcanti","year":"2011","journal-title":"Chem Res Toxicol"},{"issue":"7","key":"10.6061\/clinics\/2018\/e813s_bib73","doi-asserted-by":"crossref","first-page":"778","DOI":"10.2174\/1570180814666171012162557","article-title":"Synthesis, pharmacological evaluation and docking study of a new modulator of microtubule polymerization","volume":"15","author":"Carneiro","year":"2018","journal-title":"Lett Drug Design Disc"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib74","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1039\/np9910800415","article-title":"Withanolides and related ergostane-type steroids","volume":"8","author":"Glotter","year":"1991","journal-title":"Nat Prod Rep"},{"issue":"8","key":"10.6061\/clinics\/2018\/e813s_bib75","doi-asserted-by":"crossref","first-page":"9462","DOI":"10.18632\/oncotarget.7051","article-title":"Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK\/STAT3 signaling","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"10.6061\/clinics\/2018\/e813s_bib76","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.lfs.2006.05.026","article-title":"Selective cytotoxicity of withaphysalins in myeloid leukemia cell lines versus peripheral blood mononuclear cells","volume":"79","author":"Rocha","year":"2006","journal-title":"Life Sci"},{"issue":"10","key":"10.6061\/clinics\/2018\/e813s_bib77","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.intimp.2009.05.011","article-title":"Restoration of stress-induced altered T cell function and corresponding cytokines patterns by Withanolide A","volume":"9","author":"Kour","year":"2009","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.6061\/clinics\/2018\/e813s_bib78","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1021\/np0001068","article-title":"Antifeedant activity of withanolides from Salpichroa origanifolia on Musca domestica","volume":"63","author":"Mareggiani","year":"2000","journal-title":"J Nat Prod"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib79","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.intimp.2005.09.007","article-title":"Physalins B, F and G, seco-steroids purified from Physalis angulata L., inhibit lymphocyte function and allogeneic transplant rejection","volume":"6","author":"Soares","year":"2006","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib80","first-page":"1243","article-title":"Isolation of withaferin A from Withania somnifera Dun leaves and its antibacterial activity","volume":"18","author":"Shanazbanu","year":"2006","journal-title":"Asian J Chem"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib81","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1074\/jbc.M113.496844","article-title":"Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of \u03b2-tubulin","volume":"289","author":"Antony","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2014.06.022","article-title":"Withaferin A modulates the Spindle assembly checkpoint by degradation of Mad2-Cdc20 complex in colorectal cancer cell lines","volume":"91","author":"Das","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.6061\/clinics\/2018\/e813s_bib83","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/np400441f","article-title":"Withaferin-A induces mitotic catastrophe and growth arrest in prostate cancer cells","volume":"76","author":"Roy","year":"2013","journal-title":"J Nat Prod"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2018\/e813s_bib84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/01635580802381477","article-title":"Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells","volume":"60","author":"Stan","year":"2008","journal-title":"Nutr Cancer"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib85","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chembiol.2007.04.010","article-title":"The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin","volume":"14","author":"Bargagna-Mohan","year":"2007","journal-title":"Chem Biol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio755","article-title":"Actin microfilament aggregation induced by withaferin A is mediated by annexin II","volume":"2","author":"Falsey","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib87","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bcp.2009.09.017","article-title":"Withaferin A targets heat shock protein 90 in pancreatic cancer cells","volume":"79","author":"Yu","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib88","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/mol.106.030015","article-title":"The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from \u201cIndian winter cherry\u201d","volume":"71","author":"Yang","year":"2007","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib89","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-2004-827156","article-title":"Cytotoxic epimeric withaphysalins from leaves of Acnistus arborescens","volume":"70","author":"Veras","year":"2004","journal-title":"Planta Med"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib90","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1021\/np0340347","article-title":"Cytotoxic withaphysalins from the leaves of Acnistus arborescens","volume":"67","author":"Veras","year":"2004","journal-title":"J Nat Prod"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib91","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10637-011-9649-x","article-title":"Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens","volume":"30","author":"Rocha","year":"2012","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.6061\/clinics\/2018\/e813s_bib92","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/PL00013958","article-title":"Flavonoids of leguminous plants: structure, biological activity, and biosynthesis","volume":"113","author":"Aoki","year":"2000","journal-title":"J Plant Res"},{"issue":"38","key":"10.6061\/clinics\/2018\/e813s_bib93","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1016\/S0040-4039(00)87726-6","article-title":"Structures of cabenegrins AI and A-II, potent anti-snake venoms","volume":"23","author":"Nakagawa","year":"1982","journal-title":"Tetrahedron Lett"},{"issue":"6","key":"10.6061\/clinics\/2018\/e813s_bib94","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0960-894X(00)80321-2","article-title":"Synthetic pterocarpans with anti-HIV activity","volume":"3","author":"Engler","year":"1993","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1021\/np0502600","article-title":"Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities","volume":"69","author":"Salem","year":"2006","journal-title":"J Nat Prod"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11101-007-9059-z","article-title":"Pterocarpans: interesting natural products with antifungal activity and other biological properties","volume":"7","author":"Jim\u00e9nez-Gonz\u00e1lez","year":"2008","journal-title":"Phytochem Rev"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib97","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1042\/BJ20091127","article-title":"A natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I","volume":"425","author":"Tesauro","year":"2010","journal-title":"Biochem J"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib98","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr300219y","article-title":"Synthesis, stereochemistry, structural classification, and chemical reactivity of natural pterocarpans","volume":"113","author":"Goel","year":"2013","journal-title":"Chem Rev"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib99","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1021\/np049854d","article-title":"Cytotoxic flavonoids from Platymiscium floribundum","volume":"68","author":"Falc\u00e3o","year":"2005","journal-title":"J Nat Prod"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11418-006-0118-3","article-title":"Comparative cytotoxicity of 2, 3, 9-trimethoxypterocarpan in leukemia cell lines (HL-60, Jurkat, Molt-4, and K562) and human peripheral blood mononuclear cells","volume":"61","author":"Milit\u00e3o","year":"2007","journal-title":"J Nat Med"},{"issue":"20","key":"10.6061\/clinics\/2018\/e813s_bib101","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.lfs.2005.09.044","article-title":"Induction of apoptosis by pterocarpans from Platymiscium floribundum in HL-60 human leukemia cells","volume":"78","author":"Milit\u00e3o","year":"2006","journal-title":"Life Sci"},{"key":"10.6061\/clinics\/2018\/e813s_bib102","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biochi.2014.06.005","article-title":"Pterocarpans induce tumor cell death through persistent mitotic arrest during prometaphase","volume":"104","author":"Milit\u00e3o","year":"2014","journal-title":"Biochimie"},{"issue":"19","key":"10.6061\/clinics\/2018\/e813s_bib103","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1016\/j.bmc.2007.06.016","article-title":"New chemical tools for investigating human mitotic kinesin Eg5","volume":"15","author":"Klein","year":"2007","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib104","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-006-0254-1","article-title":"Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells","volume":"59","author":"M\u00fcller","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.6061\/clinics\/2018\/e813s_bib105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1083\/jcb.150.5.975","article-title":"Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5","volume":"150","author":"Kapoor","year":"2000","journal-title":"J Cell Biol"},{"issue":"7","key":"10.6061\/clinics\/2018\/e813s_bib106","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cbic.200500005","article-title":"Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5","volume":"6","author":"Gartner","year":"2005","journal-title":"ChemBioChem"},{"issue":"18","key":"10.6061\/clinics\/2018\/e813s_bib107","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol Biol Cell"},{"issue":"5","key":"10.6061\/clinics\/2018\/e813s_bib108","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"10.6061\/clinics\/2018\/e813s_bib109","article-title":"Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish","volume":"6","author":"Shi","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.6061\/clinics\/2018\/e813s_bib110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural Products as Sources of New Drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J Nat Prod"},{"issue":"2","key":"10.6061\/clinics\/2018\/e813s_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ph11020032","article-title":"Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:59:36Z","timestamp":1761721176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222011553"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322018000200338&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/natural-products-as-new-antimitotic-compounds-for-anticancer-drug-development\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":111,"alternative-id":["S1807593222011553"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e813s","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural products as new antimitotic compounds for anticancer drug development","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e813s","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e813s"}}